LEGN vs. ASND, CTLT, ITCI, CERE, VKTX, UTHR, SRPT, CYTK, JAZZ, and ELAN
Should you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include Ascendis Pharma A/S (ASND), Catalent (CTLT), Intra-Cellular Therapies (ITCI), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Cytokinetics (CYTK), Jazz Pharmaceuticals (JAZZ), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical preparations" industry.
Ascendis Pharma A/S (NASDAQ:ASND) and Legend Biotech (NASDAQ:LEGN) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk.
Legend Biotech has lower revenue, but higher earnings than Ascendis Pharma A/S. Legend Biotech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Legend Biotech. MarketBeat recorded 12 mentions for Ascendis Pharma A/S and 10 mentions for Legend Biotech. Ascendis Pharma A/S's average media sentiment score of 0.31 beat Legend Biotech's score of 0.26 indicating that Legend Biotech is being referred to more favorably in the news media.
Ascendis Pharma A/S has a net margin of -180.61% compared to Ascendis Pharma A/S's net margin of -181.75%. Ascendis Pharma A/S's return on equity of -37.19% beat Legend Biotech's return on equity.
Ascendis Pharma A/S received 349 more outperform votes than Legend Biotech when rated by MarketBeat users. Likewise, 65.48% of users gave Ascendis Pharma A/S an outperform vote while only 63.33% of users gave Legend Biotech an outperform vote.
70.9% of Legend Biotech shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Ascendis Pharma A/S has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.
Ascendis Pharma A/S currently has a consensus target price of $173.25, indicating a potential upside of 26.52%. Legend Biotech has a consensus target price of $82.64, indicating a potential upside of 86.05%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Legend Biotech is more favorable than Ascendis Pharma A/S.
Summary
Legend Biotech beats Ascendis Pharma A/S on 10 of the 18 factors compared between the two stocks.
Get Legend Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Legend Biotech Competitors List
Related Companies and Tools
